Summary
When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the pharmaceutical industry to develop interventions to curb these potential disasters. This case study analyzes how the industry responded to the Ebola outbreak, and how it compares and contrasts to the current COVID-19 outbreak.
Compare and contrast the pharmaceutical industry's response to a previous outbreak (Ebola) to that for COVID-19.
Scope
Reasons to Buy
When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the pharmaceutical industry to develop interventions to curb these potential disasters. This case study analyzes how the industry responded to the Ebola outbreak, and how it compares and contrasts to the current COVID-19 outbreak.
Compare and contrast the pharmaceutical industry's response to a previous outbreak (Ebola) to that for COVID-19.
Scope
- Development landscape and industry response to outbreaks
Reasons to Buy
- Understand the global epidemiology of COVID-19
- Obtain a snapshot of epidemiological trends to date in the top three most-affected countries
- Access an overview of the pipeline for therapeutics and vaccines
- Stay up to date on available efficacy data for pipeline-stage products
- View the clinical trials landscape by across key attributes
- Get up to speed on highlights in deal-making trends, particularly public-private partnerships
- Monitor top trends in social media coverage
Table of Contents
1 Executive Summary
2 Epidemiology
3 Pipeline Overview
4 Clinical Trials
5 Deal-making Trends
6 Social Media Trends
7 Key Findings
8 Appendix
9 About the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck
- Regeneron CanSino
- Johnson & Johnson
- GlaxoSmithKline
- Gilead
